Prosecution Insights
Last updated: November 20, 2026
Application No. 18/716,589

Serotonin Receptor Agonists and Methods of Making and Using the Same

Non-Final OA §102
Filed
Jun 05, 2024
Priority
Dec 22, 2021 — provisional 63/292,567 +3 more
Examiner
SHAMEEM, GOLAM M
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kuleon LLC
OA Round
1 (Non-Final)
87%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 87% — above average
87%
Career Allowance Rate
782 granted / 901 resolved
+26.8% vs TC avg
Strong +16% interview lift
Without
With
+15.8%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
37 currently pending
Career history
927
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
5.1%
-34.9% vs TC avg
§102
18.0%
-22.0% vs TC avg
§112
23.7%
-16.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 901 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority PNG media_image1.png 56 342 media_image1.png Greyscale , is acknowledged. Status of Claims Claims 22-37 are currently pending in the application. Claims 38-41 have been cancelled. Receipt is acknowledged of amendment / response filed on August 05, 2026 and that has been entered. Information Disclosure Statement Receipt is acknowledged of Information Disclosure Statement (IDS), filed on 08/13/2024, which has been entered in the file. Response to Election/Restriction In response to the restriction requirement Applicants have elected Group I, which includes claims 22-37, drawn to a compound of Formula II and the elected species as set forth and found to a compound and recited in claim 32, such as, PNG media_image2.png 134 182 media_image2.png Greyscale , without traverse, is acknowledged. Claims 38-41 (currently cancelled) are withdrawn from further consideration pursuant to 37 C.F.R. 1.142 (b) as being drawn to a non-elected subject matter. Applicants preserve their right to file a divisional on the non-elected subject matter. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 22-37 are rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Alexander et al (2020). Applicant claims a compound of Formula II (Serotonin Receptor Agonists), pharmaceutical compositions and their method of uses thereof. Alexander et al also discloses an identical compound and composition, which anticipates the instantly claimed inventions [ PNG media_image3.png 32 418 media_image3.png Greyscale PNG media_image4.png 112 430 media_image4.png Greyscale , W1 is NR1, wherein R1 is hydrogen, W3 is NR1a, wherein R1a is alkyl and Z4 is CR4, wherein R4 is alkoxy group, STN International, CAPLUS database, Accession Number 2020 : 2543665, a copy is provided with this Office action]. Claims 22-37 are rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Olson et al (2020). Applicant claims a compound of Formula II (Serotonin Receptor Agonists), pharmaceutical compositions and their method of uses thereof. Olson et al also discloses several identical compounds and compositions, which anticipate the instantly claimed inventions [ PNG media_image5.png 338 446 media_image5.png Greyscale PNG media_image3.png 32 418 media_image3.png Greyscale , W1 is NR1, wherein R1 is hydrogen, W3 is NR1a, wherein R1a is alkyl, Z4 is CR4, wherein R4 is alkoxy group, Z5 is CR5 , wherein R5 is alkyl or alkoxy group and Z6 is CR6, wherein R6 is alkoxy group, STN International, CAPLUS database, Accession Number 2020 : 1716155, a copy is provided with this Office action]. Claims 22-37 are rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Matsumura et al (2017). Applicant claims a compound of Formula II (Serotonin Receptor Agonists), pharmaceutical compositions and their method of uses thereof. Matsumura et al also discloses several identical compound and compositions, which anticipate the instantly claimed inventions [ PNG media_image6.png 282 418 media_image6.png Greyscale PNG media_image3.png 32 418 media_image3.png Greyscale , W1 is O, W3 is NR1a, wherein R1a is hydrogen or alkyl group and Z4 is CR4, wherein R4 is alkoxy group, STN International, CAPLUS database, Accession Number 2017 : 932518, a copy is provided with this Office action]. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 7:30 AM - 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks, Ph.D. can be reached at (571) 270-7682. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600. /GOLAM M SHAMEEM/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jun 05, 2024
Application Filed
Feb 11, 2025
Response after Non-Final Action
Oct 21, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797381
METHODS OF TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH OPIATE WITHDRAWAL OR OPIATE RELAPSE
2y 11m to grant Granted Nov 17, 2026
Patent 12797360
SAFER PSYCHOACTIVE COMPOSITIONS
2y 10m to grant Granted Nov 17, 2026
Patent 12790315
PYRIDYL-CONTAINING COMPOUND
2y 6m to grant Granted Nov 10, 2026
Patent 12790294
DEUTERATED FUNCTIONALIZED DERIVATIVES OF alpha-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES
2y 5m to grant Granted Nov 10, 2026
Patent 12778941
SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY
3y 6m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
87%
Grant Probability
99%
With Interview (+15.8%)
1y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 901 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month